A Danish study shows that individuals with type 2 diabetes face nearly twice the risk of cancer compared to the general population, with the gap widening over the past 25 years, highlighting the need for integrated prevention and early detection strategies.
Cancer appears to be about twice as common in people with type 2 diabetes as in the general population, according to a Danish study due to be presented at the European Association for the Study of Diabetes meeting in Milan later this month. The researchers said the gap has widened over the past 25 years, adding to evidence that cancer should be treated as a major long-term complication of diabetes alongside heart and kidney disease.
The study team, led by Tinne Laurberg of Steno Diabetes Centre Aarhus at Aarhus University Hospital, analysed health records for all adults living in Denmark between 1996 and 2022. They reported 16.6 cancer cases per 1,000 person-years among people with type 2 diabetes, compared with 7.7 per 1,000 among those without diabetes. Person-years measure both the number of people studied and the length of time they are followed.
The increased burden was especially marked for cancers linked to obesity. According to the researchers, obesity-related cancers were 45% more common in men with type 2 diabetes and 30% more common in women between 2010 and 2022. Breast cancer was modestly more frequent among women with diabetes, while colon cancer was more common in both sexes. Pancreatic cancer stood out most sharply, occurring at roughly two and a half times the rate seen in other people.
Laurberg said the findings support wider recognition of cancer as a major complication of diabetes and argued that prevention and early detection should become part of routine long-term care. She also pointed to existing screening programmes for colorectal and postmenopausal breast cancer, saying people with type 2 diabetes should be helped to use them fully. The study was not designed to show why the association exists, so the researchers said more work is needed to determine whether biological mechanisms, shared risk factors such as obesity, or other factors are driving the pattern.
The new findings fit into a broader but unsettled research picture. A national observational study published previously reported higher cancer incidence and mortality among people with type 2 diabetes, with particularly strong risks for liver, pancreatic and uterine cancer, and suggested cancer could become the leading cause of death in this group by 2030. By contrast, Mendelian randomisation studies have produced mixed results: one found genetic liability to type 2 diabetes was linked to higher odds of pancreatic, kidney, uterine and cervical cancer, while another found little evidence of a strong genetic connection to overall or site-specific cancer risk in a Japanese population. That contrast underlines that the relationship is real enough to matter clinically, but still not fully understood.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
